<DOC>
	<DOCNO>NCT01608009</DOCNO>
	<brief_summary>The purpose study assess [ 18F ] -fluciclatide biomarker response pazopanib evaluate efficacy safety combination pazopanib paclitaxel platinum-resistant ovarian cancer patient .</brief_summary>
	<brief_title>18FFluciclatide-PET , Pazopanib Paclitaxel Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Age ≥ 18 year Diagnosis relapse ovarian cancer Responded least one line prior platinum base therapy Relapsed within platinum resistant interval ( ≤6months ) Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 Measurable disease define lesion accurately measure least one dimension long diameter ≥25mm use conventional technique Satisfactory baseline haematologic organ function : Haematologic : Absolute neutrophil count &gt; = 1.5 X 10^9/L ; Platelets &gt; = 100 X 10^9/L ; Haemoglobin &gt; = 9g/dL ; PT INR &lt; = 1.2 x ULN ; PTT &lt; = 1.2 x ULN Hepatic : Bilirubin &lt; = 1.5 X ULN ; AST ALT &lt; = 2.5 X ULN Renal : Serum creatinine &lt; = 1.5 mg/dL ; Or &gt; 1.5 mg/dL , calculate creatinine clearance &gt; = 50mL/min ; UPC &lt; 1 Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥140 mmHg diastolic blood pressure ( DBP ) ≥ 90mmHg ] . Note : Initiation adjustment antihypertensive medication ( ) permit prior study entry . BP must reassess two occasion separate minimum 1 hour ; occasion , mean ( 3 reading ) SBP / DBP value BP assessment must &lt; 140/90 mmHg order subject eligible study . Treatment follow anticancer therapy : radiation therapy 28 day prior first dose pazopanib OR surgery tumor embolization within 14 day prior first dose pazopanib OR chemotherapy , immunotherapy , biologic therapy , investigational therapy hormonal therapy within 14 day five halflives drug ( whichever longer ) prior first dose pazopanib Treatment antiangiogenic therapy Presence gross ascites Clinically significant peripheral neuropathy Females childbearing potential unwilling avoid pregnancy , duration study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>platinum resistant</keyword>
	<keyword>ovarian cancer</keyword>
</DOC>